Clinical articles

Cardiac screening in the community is limited by time, resources and cost. We evaluated the efficacy of a novel smartphone application to provide a rapid electrocardiogram (ECG) screening method on the Island of Jersey, population 98,000.

Members of the general public were invited to attend a free heart screening event, held over three days, in the foyer of Jersey General Hospital. Participants filled out dedicated questionnaires, had their blood pressure checked and an ECG recorded using the AliveCor (CA, USA) device attached to an Apple (CA, USA) iPhone 4 or 5. 

There were 989 participants aged 12–99 years evaluated: 954 were screened with the ECG application. There were 54 (5.6%) people noted to have a potential abnormality, including suspected conduction defects, increased voltages or a rhythm abnormality requiring further evaluation with a 12-lead ECG. Of these, 23 (43%) were abnormal with two confirming atrial fibrillation and two showing atrial flutter. Other abnormalities detected included atrial and ventricular ectopy, bundle branch block and ST-segment abnormalities. In addition, increased voltages meeting criteria for left ventricular hypertrophy (LVH) on 12-lead ECG were detected in four patients leading to one diagnosis of hypertrophic cardiomyopathy.

In conclusion, this novel ECG application was quick and easy to use and led to the new diagnoses of arrhythmia, bundle branch block, LVH and cardiomyopathy in 23 (2.4%) of the total patients screened. Due to its highly portable nature and ease of use, this application could be used as a rapid screening tool for cardiovascular abnormalities in the community.

Sustainability of health benefits from cardiac rehabilitation (CR) requires adequate changes in lifestyles. Preventive medicine highlights a triadic guideline referring to cardioprotective behaviour, avoidance of associated polymorbid developments (e.g. depression), and improvement of life-quality. To assess the influence of long-term CR management (in Austria phase 4) offered by the Austrian Heart Association (ÖHV) on changes in lifestyles according to the INTERHEART CHD-risk parameters, a questionnaire measuring the extent of phase 4 influences on lifestyle modifications according to the INTERHEART parameters physical activity, stress, nutrition, body mass index (BMI), smoking, and alcohol was developed. Data were gained from a non-preselected sample of cardiac patients with various diagnoses (n=204; age 41–91, average 71.8; standard variation 7.8, 48% cardiovascular). 

ÖHV activities were found to exert a strong influence on health sports (various indoor and outdoor aerobic activities and mobility exercises), stress-reduction, and nutritional adjustment, contrasting low influence on the awareness of diabetes risks and alcohol/nicotine consumption. Social inclusion is considered an important life-quality factor supporting also the sense of security. 

Long-term CR management is an efficient instrument for cardioprotective lifestyle modification. The important influence on patients requires especially high sports cardiologic standards and psycho-educational competence. Close collaboration between different phases/stages of CR, as well as similar international organisation should be fostered. 

While the primary aims of cardiac surgical procedures are to improve survival and ameliorate symptoms, chronic post-surgical pain (CPSP) is a prevalent problem requiring focused attention. Recent years have seen a global emphasis on the development and implementation of self-management (SM) interventions to combat the negative consequences of multiple chronic conditions, including chronic pain. This short report makes recommendations for optimising SM following cardiac surgery to improve pain and related functional outcomes and reduce the risk and impact of CPSP.

This paper describes the experiences of developing a non-medical, non-catheter laboratory (cath lab) based implantable loop recorder (ILR) service. ILRs are small subcutaneous single-lead electrocardiogram (ECG) monitoring devices that are placed in a left pectoral pocket under local analgesia. Traditionally, devices have been implanted by medical staff in the cath lab. Each implant can take between 30 and 45 minutes depending on operator skill and patient anatomy. The development of this service has had several major patient and organisational benefits that include shorter waiting times, less cancellations and increased flexibility to implant ‘urgent’ devices in transient loss of consciousness (TLOC). The latter has reduced length of stay within our emergency assessment unit (EAU). Moreover, this service means that the department has been able to undertake more procedures in the cath lab. Data from 2013–14 suggest that an additional 32 × four-hour cath lab sessions were made available for alternative use. Adverse events (infection/erosion) are comparable with published data at less than 1%. To conclude, non-medical, non-cath lab based implantation is safe, cost-effective and has the potential to improve patient experience while increasing both cardiologist and cath lab capacity. 

Contrast-induced nephropathy is the third most common cause of in-hospital acute kidney injury and accounts for 10% of total cases. It is commonly encountered following coronary angiography and this systematic review aims to use current evidence to ascertain which treatment modalities are most effective in the prevention of the disease. 

A PubMed literature search was conducted in March 2014 using search terms, ‘contrast nephropathy and coronary angiography’. The data analysed included 15 trials and two meta-analyses in order to determine whether patients given N-acetylcysteine (NAC), sodium chloride or sodium bicarbonate had better clinical outcomes. Study data were reviewed and quality of data discussed. 

Current data indicate that sodium bicarbonate is as effective as sodium chloride when used in patients with estimated glomerular filtration rate (eGFR) <60 ml/min. NAC adds no statistically significant benefit in mild-to-moderate renal disease regardless of whether it is used in isolation or as an adjunct therapy with fluid.

The European Medicines Agency (EMA) has mandated that patients treated with dronedarone have regular monitoring. An arrhythmia specialist nurse (ASN) took over the care of patients on dronedarone in 2012.

Patients on dronedarone were identified from hospital notes and pharmacy records. Adherence to EMA guidelines on monitoring before and after the appointment of an ASN were compared. In 112 patients on dronedarone in the year prior to the appointment of an ASN, only 478 of the 1,275 (37%) required tests were actually done. With the ASN, 382 of 422 (92%) tests in 53 patients were performed. This was significantly better (p<0.001). Dronedarone was more likely to be stopped due to contraindications (p<0.017) prior to the appointment of ASN, but afterwards was more likely to be stopped due to side effects (p<0.001).

The ASN significantly improved adherence to EMA-mandated monitoring in patients on dronedarone. Involvement of an ASN had no overall impact on the likelihood of dronedarone being stopped. Patients were more likely to have the drug stopped due to side effects, and were less likely to stop for safety reasons. ASN care is superior to conventional follow-up, and is the gold standard for patients treated with dronedarone.

Percutaneous coronary intervention (PCI) has established itself as an effective alternative to coronary artery bypass graft surgery (CABG) in appropriate patients. However, the proportion of patients that undergo CABG and/or valve surgery (VS) following PCI in the short and long term is currently unknown.

We conducted a single-centre, retrospective study examining the indications and number of patients requiring CABG and or VS following successful PCI between 2009 and 2012. The surgical procedure was categorised as early (referred within <1 month of the index PCI), mid-term (referred 1–12 months after index PCI) and remote (referred >1 year and up to four years following the index PCI). 

During each three-year period (2008–2010, 2009–2011), 5,244 PCIs were performed at our centre. The total number of patients referred for cardiac surgery post-PCI was 63 (1.2%). The number of patients referred for early, mid-term and remote cardiac surgery was 21 (0.4%), 14 (0.26%) and 28 (0.53%), respectively. Within the early group, eight patients had extensive three-vessel disease stabilised with emergency/urgent PCI to allow subsequent CABG, while 10 patients had failed PCI to a chronic total occlusion. In the mid-term group, the main reason for surgery was rapid progression in coronary disease. In the remote group, the majority of patients underwent surgery for progression of valve disease. 

Our data suggest that the number of patients requiring CABG and/or VS following PCI is small, and the indications differ with time following the index PCI. We hope that these results will provide reassurance and interest to our interventional colleagues. 

A 53-year-old woman presented with history of exertional chest pain. A coronary angiogram subsequently showed an unusual and rare coronary artery anatomy: all of her coronary arteries originate from the right coronary cusp, with separate ostia. In addition, the left anterior descending (LAD) artery was hypoplastic resulting in ischaemia.

Identification of those at low risk of developing heart failure (HF) after acute coronary syndrome (ACS) would aid clinical management, but it is unclear whether N-terminal pro-brain natriuretic peptide (NT-proBNP) adds to the predictive accuracy of troponin. There were 229 subjects recruited into a prospective cohort study. Subjects were assessed for acute heart failure (AHF) prior to discharge and for readmission within 30 days of their ACS event (cohorts A+B). Cohort A (n=116) were further assessed for readmission within 12 months. Troponin I (TnI) and NT-proBNP levels were measured at ACS onset and at 6–12 hours. Readmissions were identified using electronic records. In total, 23.6% of subjects developed AHF during the index admission: 10.0% were readmitted within 30 days of admission; 17.2% within three months; 26.7% within six months and 36.2% within 12 months. At presentation, NT-proBNP, but not TnI, was significantly elevated among subjects who developed AHF compared with non-AHF subjects. Compared with non-readmitted subjects, readmission within 30 days was associated with significantly lower baseline NT-proBNP, and readmission after 30 days with higher baseline NT-proBNP. For all periods, TnI level was lower among readmitted compared with non-readmitted subjects. In conclusion, NT-proBNP has a potential role for rule out of those at low risk of AHF development and readmission. 

In a previous issue of the BJC, key issues regarding the use of high-sensitivity troponin and its use in clinical context were raised.¹ Despite the clear benefits with regards to earlier identification of ‘troponin-positive patients’, it is vital to highlight that troponin is specific for myocardial injury, but is not specific for the diagnosis of acute myocardial infarction (MI). Echocardiography is increasingly being used in cases where a ‘troponin-positive event’ is out of keeping with the history and examination for a type I MI. Competent use of this imaging modality can have drastic alterations in the management of patients and potentially prevent invasive cardiological procedures that may later provide more risk than benefit. This case report highlights the caution we must take when requesting troponin biomarkers and the use of echocardiography to aid in the management of the haemodynamically unstable patient.